The problem was resolved Thursday, when lawmakers sent a $240 million supplemental budget to Governor Maura Healey, which she ...

Scripta Insights, the doctor-driven, AI-powered pharmacy navigation company that guides self-insured employers, health plans ...

An FDA deadline instructing compounding pharmacies and telehealth companies to stop selling compounded versions of Ozempic and Zepbound has not stopped the copycat market, The Wall Street Journal ...

The popularity of GLP-1 drugs has insurance companies scrambling to satisfy consumer access while reining in exorbitant costs.

Novo Nordisk NVO shares have gained 13.9% in the past month. Several factors related to the company’s pipeline, regulatory ...

Illinois officials indicated that the settlement is about a larger issue than just a contract dispute with one PBM.

Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...

Even if the order takes effect, it will do nothing to address the root causes of the problem it purports to solve.

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Other factors can affect access. This week, CVS Health said Wegovy will become the preferred option on its standard formulary ...